Introduction
Prostate cancer is the second leading cause of cancer death in men and one of the most therapy resistant cancers. 1 Few therapies are available for the treatment of advanced states of prostate cancer because the cancer cells are androgen-independent and the primary therapy of androgen ablation ceases to have an effect. 2 Chemotherapy is a common strategy used to treat various forms of cancer, including prostate cancer. The mechanism by which many chemotherapeutic drugs act is by targeting cancer cells to undergo apoptosis. Most prostate cancers initially respond to androgen ablation by undergoing apoptosis but this therapy selects for cancer cells that are androgen insensitive. 3 Interestingly, these androgen insensitive cells still maintain the proper apoptotic machinery suggesting that these cells may be targets for novel chemotherapeutic agents.
Recent studies indicate that in prostate cancer aberrant expression of important apoptosis proteins, such as Bcl-2 and Bax, may be responsible for the androgen refractory phenotype. 4 Bcl-2 is a potent anti-apoptotic protein that regulates the release of cytochrome C from the mitochondria and Bax is an important pro-apoptotic protein that is known to heterodimerize with Bcl-2 and affect the ability of Bcl-2 to block apoptosis. 5 Studies have shown that normal prostate cells express little or no Bcl-2 whereas prostate cancer cells and metastatic prostate cancer cell lines such as DU145, PC3, and LNCaP express various amounts of this protein. 6 -8 The LNCaP prostate cancer cell line is one of the few androgen-responsive cell lines available for the study of androgen-responsive prostate cancer. Often, LNCaP cells are compared to androgen-unresponsive cell lines such as DU145 or PC3 to draw comparisons between androgenresponsive and androgen-unresponsive characteristics. The limitations of such comparisons include the fact that each of these three cell lines were derived from different sources and comparisons between the three cannot take into account the diversity of different genetic backgrounds. Understanding the molecular mechanisms during the progression of prostate cancer to an androgenunresponsive state requires a cell model with the same genetic background. The androgen-responsive LNCaP prostate cancer cell line becomes androgen-unresponsive at high passage numbers, 9 providing a unique model to study the clinical progression of prostate cancer to an androgen-unresponsive state.
Among the prostate cancer cell lines, LNCaP cells exhibit a wild type p53, while DU145 cells contain two mutations in the p53 gene and the PC3 cells are null for p53. 10 Androgen receptor, prostate specific antigen and prostatic acid phosphatase are all expressed in LNCaP cells, though Lin et al. 9 showed that high passage androgen-independent LNCaP cells had decreased expression of prostatic acid phosphatase. The androgen receptor expressed in LNCaP cells contains a mutation in the hormone-binding domain that affects the response of these cells to steroid binding and to anti-androgens. 11 The result of this mutation in the androgen receptor in LNCaP cells causes the cells to respond with high affinity to estrogens and some anti-androgens. 12 The LNCaP prostate cancer cell line maintains the proper apoptotic machinery and can be induced to undergo apoptosis. Tang et al. 7 showed that LNCaP cells express Bcl-2, Bax, Bcl-xL and Bak and are more sensitive to the induction of apoptosis when compared with DU145 and PC3 cells. Induction of apoptosis in LNCaP cells and an androgen-independent subline, LNCaP-AI, was shown to occur via activation of Rb. 13 We investigated the regulation of expression of the Bcl-2 family of proteins during the progression towards androgen-unresponsiveness utilizing the LNCaP prostate cancer cell model. It had previously been reported that early passage LNCaP cells (passages 20 -33) are androgen-dependent, while the later passages (passage 80 and higher) are androgen-independent. 9 We used an extension of this established model. In our model, LNCaP-R cells are from passages 20 to 50, are androgen-responsive, and slow in growth. LNCaP-RF cells are from passages 50 to 95, are somewhat androgen-responsive, and faster growing than LNCaP-R. LNCaP-UR cells comprise passages higher than 95, are androgenunresponsive, and fast growing. Utilizing this model, we seek to determine what changes occur in the Bcl-2 family of apoptosis regulators that may contribute to the progression of prostate to an androgen-independent state.
Materials and methods

Cell culture
LNCaP, DU145, and PC3 cells were maintained in RPMI1640 supplemented with 7% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) (Gibco-BRL, Life Technologies, Inc. Grand Island, NY, USA). MCF7 cells were maintained in DMEM supplemented with 7% FBS and 1% PS (Life Technologies, Inc. Grand Island, NY, USA). MDAPCa 2A and 2B cells were maintained in BRFF media (Biological Research Faculty and Facility, Inc. Ijamsville, MD, USA) supplemented with 20% FBS and 1% PS. Cells were routinely fed with fresh media, passaged as needed, and maintained in a 37 C incubator at 5% CO 2 .
DHT stimulation experiment
LNCaP cells were treated with dihydrotestosterone (DHT) (Sigma Chemical Co, St Louis, MO, USA) and growth stimulation was measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma Chemical Co.) assay. Prior to measuring DHT stimulation, a standard curve of various cell numbers and absorbance from the MTTassay was generated. A total of 20 000, 40 000, 60 000, 80 000, 100 000 and 120 000 cells were seeded into six-well plates from each of the representative LNCaP cells. Cells were allowed to sit down for 48 h then processed for MTT assay. For MTT assay, cells were rinsed once with phenol red-free HBSS and 2.0 ml MTT (dissolved in serumfree, phenol red-free RPMI 1640) was added to each well and placed in a 37 C incubator for 4 h. After the incubation period, MTT reagent was removed and 2.0 ml of 99% isopropanol was added to dissolve the product. A total of 100 ml of each sample was placed into a 96-well plate and the absorbance was read at 590 nm using a Spectra Max 190 (Molecular Devices, Sunnyvale, CA, USA).
For DHT stimulation, a total of 3610 4 cells from each representative of the LNCaP model (R, RF and UR) were seeded into 6-well plates using RPMI 1640 supplemented with 7% FBS and 1% PS. After 2 days the media was aspirated, the cells were rinsed once with phenol red-free HBSS, and phenol red-free RPMI 1640 containing 2% charcoal stripped FBS was added. After 1 day, the media was aspirated and cells (in triplicate) were fed with phenol red-free RPMI 1640 with 2% charcoal stripped FBS and 1610 78 M DHT. Control cells (in triplicate) were fed with phenol red-free RPMI1640 with 2% charcoal stripped FBS. MTT assay was performed after 4 days of incubation with DHT.
RNase protection assay
RNase protection assays were performed using RiboQuant Ribonuclease protection assay (RPA) kit, (Pharmingen, San Diego, CA, USA). Briefly, total RNA was isolated from cells using TRIzol (Gibco-BRL) and 30 mg of total RNA was hybridized to 32 P-labeled probes for each indicated RNA message. Analysis was performed using a Storm Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). Results were normalized to the expression of GADPH as an internal control.
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Western blot analysis
Protein extracts were prepared from cells using a protein lysis buffer containing 50 mM Tris -HCl, pH 7.5, 2.0 mM phenylmethylsulfonyl fluoride (PMSF), 5.0 mM iodoacetamide, 5.0 mM ethylene diamine tetra-acetic acid (EDTA), 150 mM NaCl, 0.5% nonylphenoxy polyethoxy ethanol (NP-40), and 0.5% nonanoyl-N-methylglucamide (Mega-9). Protein concentrations in the extracts were quantitated using bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). From each extract, 50 mg of total protein was separated on a 12% SDS-PAGE. After electrophoresis, proteins were transferred to PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked for 1 h at room temperature in 5% powdered milk dissolved in 1X Tween-20, Tris-buffered saline (TTBS) containing 14 mM Tris, 154 mM NaCl, and 0.1% Tween-20, pH adjusted to 7.5 with HCl. The membrane was incubated with the primary antibody for 16 h at 4 C. The antigen -antibody complexes were detected by using the appropriate secondary antibodies conjugated to horseradish peroxidase (Promega, Madison, WI, USA) at 1:2500 dilution. Membranes were developed using ECL þ (Amersham Pharmacia Biotech, Arlington Heights, IL, USA) and films exposed for 5 or 30 min. Primary antibodies used were: mouse monoclonal antihuman Bcl-2 (C-2, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:500 dilution, rabbit polyclonal anti-human Bax (N-20, Santa Cruz Biotechnology) at 1:400 dilution, mouse monoclonal anti-androgen receptor (N-20, Santa Cruz Biotechnology) at 1:1000 dilution, goat polyclonal anti-human prostate specific antigen (C-19, Santa Cruz Biotechnology) at 1:2000 dilution, mouse monoclonal anti-human Bcl-xL(H-5, Santa Cruz Biotechnology) at 1:100 dilution, and mouse monoclonal anti-human b-actin (Sigma) at 1:1000 dilution. b-actin or a rabbit polyclonal anti-human PGK antibody at a 1:2000 dilution was included in the Western blot analysis as an internal control.
PCR analysis
Bcl-2 message was characterized by PCR using the enhanced Avian RT-PCR kit (Sigma). Total RNA (5 mg) was added to each RT reaction using random nonamer primers. The cDNA products were amplified using Bcl-2 specific primers to give a 660 bp product. The forward primer (corresponding with nucleotides 1 -20 of human Bcl-2 sequence) used was 5 0 -GTTGGCCCCCGTTACT-TTTC-3 0 , and the reverse primer (corresponding to nucleotides 660 -642 of the human Bcl-2 sequence) used was 5 0 -AACAGAGGCCGCATGCTGGG-3 0 .
Confocal microscopy
LNCaP cells were grown to 80% confluence on the surface of round glass cover slips in 12-well plates. The cells were washed with HBSS and blocked for 1 h in SuperBlock blocking buffer (Pierce, Rockford, IL, USA). Cells were then incubated with anti Bcl-2 primary antibody at 1:500 dilution for 1 h at room temperature. Cells were washed three times in 16phosphate buffered saline (PBS), and incubated with 1:10 000 dilution of Texas Red Anti-mouse IgG secondary antibody (Vector Labs, Burlingame, CA, USA) for 1 h. Cells were washed three times in 16PBS, mounted onto glass slides using Vectashield mounting media (Vector Labs) and visualized by confocal microscopy with a Carl Zeiss Model LSM 410 microscope.
TUNEL assay
Cells were seeded onto round glass cover slips placed into 12-well plates and allowed to grow for 3 days. The cells were then washed once with HBSS and then treated with 500 mM hydrogen peroxide (H 2 O 2 ) in RPMI 1640 or left untreated and fed with RPMI 1640 and incubated for 24 h. Apoptotic cells were determined using the TUNEL assay (Roche Molecular Biochemicals, Manneheim, Germany). Briefly, cells were rinsed once in 16PBS and fixed with 4% paraformaldehyde in 16PBS for 1 h at room temperature. Cells were then rinsed with 16PBS and endogenous peroxidase activity blocked with 3% H 2 O 2 in methanol for 10 min at room temperature. Cells were permeabilized with 0.1% triton 6 7 100 in 1.0% sodium citrate buffer for 2 min on ice. After three rinses in 16PBS, cells were incubated with terminal deoxynucleotidyl transferase (TUNEL) for 1 h at 37 C. Cells were then rinsed three times in 16PBS, and incubated with labeling solution for 30 min at 37 C. Cells were then rinsed three times in 16PBS, and incubated with diaminobenzamidine (DAB) in peroxide buffer for 2 min. The coverslips were then rinsed in Milli-Q H 2 O and mounted onto glass slides. Analysis of apoptotic cells was performed under a light microscope at 4006magnification by counting positively stained nuclei.
DNA fragmentation assay
Cells were treated with 500 nM paclitaxel for 24 h, 5 mM sodium butyrate for 72 h, or left untreated for the same durations. For DNA fragmentation analysis, cells were lysed at 48 C for 30 min in a DNA lysis buffer containing 20 mM EDTA, 5 mM Tris -HCl (pH 7.4), and 0.5% (v/v) Triton 6 7 100. Lysates were clarified by centrifugation at 15000 rpm in an Eppendorf microcentrifuge for 15 min and the supernatant was treated with RNase A (20 mg/ ml) at 37 C for 30 min followed by treatment with proteinase K (20 mg/ml) for 30 min at 37 C. DNA fragments were precipitated with 95% ice -cold ethanol and pelleted by centrifugation for 15 min at 15 000 rpm in an Eppendorf microcentrifuge. DNA pellets were resuspended in Milli-Q water and subjected to electrophoresis on a 1.5% agarose gel. The gel was stained with ethidium bromide (0.5 mg/ml) and the DNA fragmentation was visualized using a Nucleovision Nucleotech Gel Expert (Hayward, CA) gel imaging workstation.
Lactate dehydrogenase assay
Determination of necrosis was performed by measuring the presence of lactate dehydrogenase (LDH) in the cell culture media. Cells were seeded and allowed to grow to 80% confluence in T75 flasks, and then treated with 5.0 mM sodium butyrate or left untreated (control) for 72 h. LDH activity present in the media of treated and Bcl-2 regulation in prostate cancer CA Rothermund et al control cells were determined using Cytotox 96 (Promega) kit. Briefly, 1.0 ml of media from each flask of treated and control cells were collected and centrifuged for 5 min at 14000 rpm at 4 C in an Eppendorf microcentrifuge. A volume of 50 ml of the centrifuged media was added in triplicate to a 96-well plate. To control for LDH present in serum contained in the media, 50 ml of serum-containing media was added in triplicate as a blank. For a positive control, 50 ml of cell lysate from the treated LNCaP cells were added in triplicate. Substrate mix (50 ml) was added to each sample and the plate incubated in darkness for 30 min at room temperature. Stop solution (50 ml) was added to each well and the absorbance at 490 nm was recorded on a Spectramax 190 plate reader (Molecular Devices).
Results
Characterization of the LNCaP progression model
We utilized the LNCaP prostate cancer cell line maintained under normal growth conditions as described in the Materials and methods section. At low passage numbers, LNCaP cells are androgen-responsive. By continued subculture under normal growth conditions, these cells become androgen-unresponsive at higher passages ( Figure 1) . Table 1 summarizes the passage numbers and designation of the LNCaP cells used in this study. We define LNCaP cell passages 20 -50 as LNCaP-responsive (LNCaP-R), passages 50 -95 as LNCaP-responsive fast growing (LNCaP-RF), and passages 95 and above as LNCaP-unresponsive (LNCaP-UR).
All representatives of the LNCaP model expressed the androgen receptor (Figure 2 , panel A) and we observed a gradual decrease in expression of the prostate specific antigen as the cells progressed from the androgen-responsive (LNCaP-R) to androgen-unresponsive (LNCaP-UR) state (Figure 2, panel B) .
The Bcl-2 family of apoptosis regulators is normal in the LNCaP model
We utilized the RNase protection assay to determine mRNA expression of Bcl-2 family of genes in LNCaP cells grown under normal conditions. Figure 3 shows the expression of various members of the Bcl-2 family normalized to GAPDH as a control. Both the anti-apoptotic (Bcl-2, Mcl-1, Bclx, and Bfl-1) and proapoptotic (Bax, Bik, and Bak) genes in the Bcl-2 family were expressed in the LNCaP-R, LNCaP-RF and LNCaP-UR cells. There were no significant differences in the expression of Bcl-2 family members in the three LNCaP cell types. We further confirmed Bcl-2 message expression in the LNCaP model by RT-PCR (Figure 4) . All three LNCaP cell types in our model showed Bcl-2 message expression, which confirmed the results of the RNase protection assay (Figure 3 ) that Bcl-2 message is present in the all representatives of the LNCaP model. Figure 5 ) as an internal control. RT-PCR confirms mRNA expression of Bcl-2 in the LNCaP model. RNA was isolated from cells using TRIzol reagent (Gibco-BRL) and reverse transcribed using Sigma Avian RT-PCR kit (Sigma-Aldrich) as described in the Materials and methods section. The PCR product of Bcl-2 was amplified using primers that targeted the 5 0 end of Bcl-2 mRNA and gave the expected 660 bp product. , lanes 2 -7) and MDAPCa cells (50 mg protein, lanes 8 and 9) were subjected to SDS-PAGE and immunoblotting as described in the Materials and methods section. The membrane was exposed to X-ray film for 5 min (panel A). Prolonged exposure of the membrane for an additional 30 min (panel B) did not result in the appearance of any additional bands. Immunoblot analysis of phosphoglycerate kinase (panel C) was included as an internal control.
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In each analysis, we also included the MCF-7 breast carcinoma cell line ( Figure 5 , Lane 1) as a positive control since these cells endogenously express high levels of Bcl-2 protein.
Bax and Bcl-xL protein levels are unchanged in the LNCaP model
Bax is an important pro-apoptotic protein thought to heterodimerize with Bcl-2 and thus promote apoptosis.
Since it is thought that the ratio of Bcl-2 to Bax determines the susceptibility of cells to undergo apoptosis, 7 we examined Bax protein levels in the LNCaP model ( Figure 6 , panel A 7, 15 Immunoblot analysis of Bcl-xL ( Figure 6, panel B) showed no changes in the Bcl-xL levels in the LNCaP model.
Confocal microscopy shows a basal level of Bcl-2 protein expression in androgen-unresponsive cells
LNCaP cells were grown on glass cover slips and subjected to immunocytochemistry to determine the cellular expression of Bcl-2. Figure 7 shows LNCaP cells stained for Bcl-2 and visualized by confocal microscopy. Androgen-unresponsive cells are resistant to apoptosis induced by oxidative stress but not by treatment with paclitaxel or sodium butyrate
In order to test whether changes in Bcl-2 levels in the LNCaP model affects the sensitivity of these cells to various apoptosis inducers, cells were treated with H 2 O 2 and examined for DNA fragmentation using the TUNEL assay. LNCaP-R, RF and UR were treated for 24 h in 500 mM H 2 O 2 to introduce oxidative damage and induce apoptosis. LNCaP-R ( Figure 8) shows a significant ) and LNCaP-UR (panel C) cells were probed for endogenous Bcl-2 protein expression in situ. Cells were grown for 3 days on glass coverslips placed into 12-well plates. Cells were processed as described in the Materials and methods section. Confocal analysis was performed using Carl Zeiss Model LSM410 microscope (6200 magnification).
Bcl-2 regulation in prostate cancer CA Rothermund et al amount of apoptosis as do the LNCaP-RF cells. However, LNCaP-UR cells show little TUNEL positive staining indicating that these cells are resistant to apoptosis induced by oxidative stress. Figure 9 shows quantitation of the TUNEL data. The data indicates the relative resistance of LNCaP-UR cells to undergo apoptosis induced by H 2 O 2 . In these cells, some changes or modifications in the apoptotic machinery have taken place to lend resistance to oxidative stress. LNCaP-R, RF and UR were induced to undergo apoptosis by treatment with 500 nM paclitaxel for 24 h. Paclitaxel is a microtubule active drug and functions by disruption of the cytoskeleton and is also thought to induce apoptosis by phosphorylation and subsequent degradation of Bcl-2 in prostate cancer cells. 16, 17 Given the loss of expression of Bcl-2 in the LNCaP-UR cells, we sought to determine if paclitaxel could induce apoptosis irrespective of Bcl-2 status. Figure 10 shows the results of a DNA ladder experiment and shows DNA fragmentation in all treated lanes suggesting that LNCaP-R, RF and UR are equally sensitive to this drug.
We also induced apoptosis in the LNCaP model with sodium butyrate. Sodium butyrate acts to disrupt cellular function and induce apoptosis by a number of mechanisms, one of which is histone deacetylation inhibition that alters gene expression. We found that treatment of the LNCaP model for 72 h with 5 mM of sodium butyrate was sufficient to induce apoptosis as evidenced by DNA fragmentation analysis (Figure 11 ). To distinguish between cell death by apoptosis or necrosis, we measured LDH activity as an indicator of necrosis ( Figure 12 ). 
Discussion
The purpose of this study was to measure changes in the Bcl-2 family of apoptosis effectors during the progression of prostate cancer from an androgen-responsive to an androgen-unresponsive state. Our focus was on Bcl-2 since this anti-apoptotic protein has been demonstrated to play an important role in androgen-insensitive prostate cancer. 4 The LNCaP prostate carcinoma cell model used in this study offered the advantage of having a similar genetic background to compare the expression of Bcl-2 in the progression of prostate cancer to an androgen-unresponsive state. Message expression of Bcl-2 was present in all representatives of the LNCaP model (Figure 3) . RT-PCR confirmed that message expression was present (Figure 4 ) which led us to further examine Bcl-2 protein levels. We expected that Bcl-2 protein expression would increase as cells became androgen-unresponsive. However, we failed to observe an increase in Bcl-2 protein expression as the LNCaP cells became androgen-unresponsive ( Figure 5 ), but observed a dramatic decrease in Bcl-2 protein levels. This finding is consistent with the observation that in many prostate cancer tissue specimens, Bcl-2 staining is negative despite a high Gleason grade and stage. 6 The finding that Bcl-2 protein expression was lost in the androgen-unresponsive LNCaP cells suggest a number of possibilities, one of which is that Bcl-2 may Figure 10 Both androgen-responsive and androgen-unresponsive cells are sensitive to paclitaxel. Cells were treated with 500 nM paclitaxel and control cells with vehicle alone (0.1% ethanol). After treatment for 24 h, cells were harvested and DNA was extracted as described in the Materials and methods section. DNA was visualized by electrophoresis in a 1.5% agarose gel stained with 0.5 mg/ml ethidium bromide. Figure 11 Both androgen-responsive and androgen-unresponsive cells are sensitive to sodium butyrate. LNCaP Cells were treated with 5.0 mM sodium butyrate for 72 h or left untreated. After 72 h, treated and control cells were harvested and DNA was extracted as described in the Materials and methods section. DNA fragments were separated and visualized by electrophoresis in a 1.5% agarose gel stained with 0.5 mg/ml ethidium bromide. Figure 12 Cell death in sodium butyrate treated and control LNCaP cells is not due to necrosis. Cells were treated with 5.0 mM sodium butyrate or left untreated for 72 h then harvested and processed for LDH determination as described in the Materials and methods section. Absorbance was read at 490 nm and data shown as absorbance values normalized to background. Each datum point represents the mean AE s.e.m. from triplicate observations from two separate experiments.
Bcl-2 regulation in prostate cancer CA Rothermund et al not be the determining factor in the progression of prostate cancer to androgen-unresponsiveness and the concomitant resistance to apoptosis. The notion that Bcl-2 is not the determining factor in apoptosis sensitivity in the LNCaP model was confirmed by subjecting the cells to oxidative stress to undergo apoptosis. We found that the LNCaP-UR cells were highly resistant despite the apparent loss of expression of Bcl-2 protein. Another possibility is that Bcl-2 may be rapidly degraded in our LNCaP-UR cells. Several studies have shown that modification of the N-terminal region of Bcl-2 targets this protein for rapid degradation. Breitschopf et al. 18 showed that dephosphorylation of serine 87 led to the proteosome-mediated degradation of Bcl-2 in HUVEC cells. Srivastava et al. 19 showed that a deletion of the loop region of Bcl-2, which removes a segment of the Nterminal region of the Bcl-2 protein abrogates the ability of cells expressing this mutant protein to undergo paclitaxel induced apoptosis. Whether or not our LNCaP-UR cells have these N-terminal modifications of Bcl-2 has yet to be determined.
The proapoptotic Bax protein is thought to heterodimerize with Bcl-2 and affect the ability of Bcl-2 to block apoptosis. It is thought that increased protein expression of Bax favors apoptosis and decreased expression of Bax favors survival. 20 Bax protein was equally expressed in all representatives of the LNCaP model ( Figure 7 ). The loss of Bcl-2 in the LNCaP-UR cells did not correspond to any change in Bax protein expression. Therefore if an increase of Bax protein targets cells for apoptosis, our LNCaP-UR cells would have been sensitive to oxidative damage. However, this was not the case (Figures 8 and 9 ). This finding suggests that the Bcl-2 to Bax protein ratio may not be the determinant of apoptosis sensitivity in LNCaP cells. Bcl-2 is the founding member of a growing family of cell survival and death arbiters and numerous examples of antiapoptotic role of Bcl-2 in cancer have been demonstrated. 21 A number of other Bcl-2 family members are yet to be characterized and their potential role in prostate cancer has yet to be elucidated. Bcl-xL is an antiapoptotic member of the Bcl-2 family and was shown to desensitize LNCaP and PC3 cells to chemotherapeutic agents when over-expressed, and sensitized these cell lines to chemotherapeutic agents when down-regulated with antisense oligonucleotides. 22 In our model, we did not observe any changes in the level of Bcl-xL protein ( Figure 6B ) in LNCaP-R, LNCaP-RF or LNCaP-UR cells.
Interestingly, when the LNCaP-model was treated with paclitaxel, all of the LNCaP cell types were equally sensitive to this drug ( Figure 10) . A number of studies report that one mechanism of action of paclitaxel is phosphorylation of Bcl-2, which targets this protein for proteosome-mediated degradation. 18, 19 Since LNCaP-UR cells do not express Bcl-2, the mechanism of paclitaxelinduced apoptosis in these cells may be a result of its microtubule disrupting action or by a yet unidentified action of the drug. Treatment of the LNCaP model with sodium butyrate showed that both our androgen-responsive and androgen-unresponsive cells were equally sensitive to the induction of apoptosis with little or no cell death by necrosis (Figures 11 and 12 ). These data suggest that androgen-unresponsive cells can be induced to undergo apoptosis by similar mechanisms as their androgen-responsive counterparts.
